Cardiac Imaging and Stress Testing Asymptomatic Athletes to Identify Those at Risk of Sudden Cardiac Death  by La Gerche, Andre et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 6 , N O . 9 , 2 0 1 3
ª 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 3 . 0 6 . 0 0 3iREVIEWSS T A T E - O F - T H E - A R T P A P E R
Cardiac Imaging and Stress Testing
Asymptomatic Athletes to Identify
Those at Risk of Sudden Cardiac Death
Andre La Gerche, MD, PHD,*y Aaron L. Baggish, MD,z Juhani Knuuti, MD, PHD,x
David L. Prior, MD, PHD,* Sanjay Sharma, MD,k Hein Heidbuchel, MD, PHD,y
Paul D. Thompson, MD¶Melbourne, Australia; Leuven, Belgium; Boston, Massachusetts; Turku, Finland;
London, United Kingdom; and Hartford, ConnecticutJACC: CARDIOVASCULAR IMAGING CME
CME Editor: Ragavendra R. Baliga, MD
This article has been selected as this issue’s CME ac-
tivity, available online at http://imaging.onlinejacc.org
by selecting the CME tab on the top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation
(ACCF) is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME
activity for a maximum of 1 AMA PRA Category 1
Credit(s). Physicians should only claim credit
commensurate with the extent of their participation
in the activity.
Method of Participation and Receipt of CME
Certiﬁcate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular
Imaging subscriber.
2. Carefully read the CME-designated article
available online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of
the 3 questions provided must be answered
correctly to obtain CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certiﬁ-
cate electronically by following the instructions
given at the conclusion of the activity.
CME Objective for This Article: At the end of this
activity the reader should be able to: 1) recognize
some of the factors associated with sudden cardiac
death (SCD) and provide some perspective regarding
the incidence of SCD; 2) recognize some of the
common and less common variants in the assessment
of athlete's heart and differentiate these from ﬁndings
suggestive of cardiac pathology; and 3) apply Bayes’
theorem to determine appropriate utilization of
diagnostic testing in athletic populations.
CME Editor Disclosure: JACC: Cardiovascular Im-
aging CME Editor Ragavendra R. Baliga, MD, has
reported that he has no relationships to disclose.
Author Disclosure: Dr. Heidbuchel has received
speakers’ fees from Boehringer-Ingelheim, Daiichi
Sankyo, Bayer, Pﬁzer, Sanoﬁ-Aventis, Medtronic,
Biotronik, and Merck; unconditional research grants
fromMedtronic, Biotronik, Boston Scientiﬁc, St. Jude
Medical, and AstraZeneca; and collaborative research
support from Siemens. Dr. Thompson owns stock in
General Electric. All other authors have reported that
they have no relationships relevant to the contents of
this paper to disclose.
Medium of Participation: Print (article only);
online (article and quiz).
CME Term of Approval:
Issue Date: September 2013
Expiration Date: August 31, 2014
La Gerche et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 9 , 2 0 1 3
Imaging Asymptomatic Athletes S E P T E M B E R 2 0 1 3 : 9 9 3 – 1 0 0 7
994Cardiac Imaging and Stress Testing Asymptomatic Athletes to Identify
Those at Risk of Sudden Cardiac DeathSudden cardiac death in young athletes is rare but tragic. The cardiology community is faced with the challenge of providing a
sensible strategy for the prevention of SCD while simultaneously reafﬁrming that the beneﬁts of regular exercise far outweigh
potential risks. At present, there is a broad range of screening recommendations dependent upon country, sporting discipline,
and competition level. While much recent debate has focused on the efﬁcacy of screening with electrocardiography, a
number of sporting bodies also mandate the inclusion of exercise testing and echocardiography in screening protocols.
Cardiac magnetic resonance imaging, coronary calcium scoring and computed tomography coronary angiography have
also been promoted as potentially valuable screening tools for competitive athletes. This review will examine the
controversial topic of utilizing cardiac imaging for athlete pre-participation screening. Speciﬁcally, the limitations of
screening for relatively rare disorders using imaging tools with uncertain or imperfect accuracy will be addressed. Current
evidence suggests that the accuracy of all cardiac imaging modalities is insufﬁcient to justify their use as primary
screening modalities in athletes. Atypical ﬁndings such as marked cardiac dilation, reduced deformation, or small patches
of delayed gadolinium enhancement may be commonly encountered in well-trained athletes, but, at present, the
prognostic signiﬁcance of such ﬁndings is unknown. Resulting uncertainty for the clinician and athlete has the potential
for psychological stress, further testing, and unnecessary exclusions from competition. However, these concerns must not
be confused with the extremely useful applications of cardiac imaging for the assessment of athletes with symptoms, an
abnormal electrocardiogram or a positive family history. As modern imaging further enhances our understanding of the
spectrum of athlete’s heart, its role may expand from the assessment of athletes with suspected disease to being part of
comprehensive pre-participation screening in apparently healthy athletes. (J Am Coll Cardiol Img 2013;6:993–1007)
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A B B R E V I A T I O N S
A N D A C R O N YM S
ARVC = arrhythmogenic right
ventricular cardiomyopathy
BAV = bicuspid aortic valve
CACS = coronary artery calcium
scoring
CHD = coronary heart disease
CTCA = computed tomography
coronary angiography
CMR = cardiac magnetic
resonance
DGE = delayed gadolinium
enhancement
ECG = electrocardiogram
HCM = hypertrophic
cardiomyopathy
LV = left ventricle
RV = right ventricle
sudden cardiac death
x = maximal oxygen
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995profound athletic cardiac remodeling and cardiac
pathology. Furthermore, the consequences of di-
agnostic inaccuracy are greater in professional ath-
letes given the potential for lost careers and
aspirations if an athlete is inappropriately dis-
qualiﬁed or, on the other hand, a potentially greater
exposure to exercise triggered SCD if an underlying
pathology is missed.
Sport and exercise are an important part of daily
life and should be encouraged for a multitude of
reasons, including improved health outcomes and
reduced SCD risk (1,2). Thus, a paradox exists
whereby exercise is associated with substantial
health beneﬁts in the vast majority but may serve as
a trigger for arrhythmias in a small minority with an
underlying pathologic substrate. Therefore, the
challenge for broad-based screening programs is to
identify those at risk while minimizing harm
through unnecessary exclusions from sport. In 1982,
with this goal in mind, cardiologists lobbied gov-
ernment policy makers in Italy resulting in a law
mandating pre-participation screening for all ath-
letes age 12 years or older. Since this time, all Italian
athletes have been required to undergo screening
comprising clinical history, physical examination
and an electrocardiogram (ECG) prior to accep-
tance in competitive sport (3). This policy has been
both lauded and criticized in equal measure. Pro-
ponents cite proof of long-term efﬁcacy among
those screened under the Italian system (3,4), while
others have argued that the incidence of SCD is
extremely low in unscreened athletic populations
and the less than perfect speciﬁcity of ECG
screening has potential for harm through unnec-
essary investigations, psychological stress, and dis-
qualiﬁcations (5–7). As the debate continues to
rage, it is becoming increasingly clear that an op-
portunity has been missed. In 1982, when evidence
for ECG screening was scarce, the medical frater-
nity and legislators could have insisted on a ran-
domized trial (screening with vs. without ECG) in
preference to uniform policy. Had this occurred, it
might well have provided the deﬁnitive experience
on which informed policy making could now be
based. Similar lessons can be extrapolated to the
topic of screening with cardiac imaging. Perhaps the
foremost priority should be for evidence to lead the
debate rather than opinion.
Potential Causes of Sudden Cardiac Death
in a 36-Year-Old Marathon Runner
The incidence of sudden death in young athletes
(#35 years) is 0.6 to 3.6 per 100,000 populationper year and the majority of deaths are due to
cardiovascular causes (3,5,8–10). For reasons that
remain unexplained, the risk is approximately
10-fold greater among males than females and is
higher among competitive athletes when compared
with nonathletes (8,9). Although considerable
attention has focused on young athletes, the risk of
SCD is greater among sports participants older
than 35 years and is greatest in the ﬁfth decade (9).
Prevention strategies aim to identify cardiac
pathologies that may serve as a substrate for
arrhythmias triggered by exercise. In general,
inherited cardiomyopathies are the most frequent
cause of SCD in young athletes while acquired
heart disease, principally coronary artery disease, is
most frequent in athletes of middle age
and older (5,8,9,11–13). However, there is
considerable overlap, particularly among
30- to 50-year-old athletes and it may
also be that the incidence of inherited
cardiomyopathies is underestimated in
this group as autopsies are less often per-
formed and coronary disease causation
more frequently presumed. It would seem
important that each of the conditions
predisposing to SCD be considered in
potential screening strategies for our
36-year old marathon runner under con-
sideration (Fig. 1).Anticipating Screening Efﬁcacy
The predictive value of a screening test
may be anticipated according to Bayes’
Theorem:PVtest¼
PpathologySensitivitytest
PpathologySensitivitytest
þPnopathologyfalsepositivetest

where PVtest is predictive value of the screening test,
Ppathology is prevalence of a condition predisposing
to sudden cardiac death, Sensitivitytest is sensitivity
of the screening test, and false positivetest is 100% –
speciﬁcity% of the screening test, respectively.
This equation for calculating probabilities provides
an instructive framework for evaluating the accuracy
of diagnostic tests for rare conditions. When the
disease prevalence is low, the probability of the test
accurately identifying that pathology (the predictive
value of the screening test) is exquisitely dependent
on the test speciﬁcity. Unless the test is highly
speciﬁc then an abnormal result on screening is most
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Figure 1. Age-Dependent Changes in Incidence and Etiology of Sudden Cardiac Death
This ﬁgure represents an interpretation of the combined experience from studies that have assessed the causes of sudden cardiac death in
athletes (3,5,8,9,11–13). While the majority of deaths may be attributed to inherited cardiomyopathies and channelopathies in those younger
than 30 years old, there is no absolute cutoff. Thus athletes in their thirties and forties (the median age in many competitive sports) are at
greatest risk of sudden cardiac death caused by inherited and acquired causes. RV ¼ right ventricular; VT ¼ ventricular tachycardia.
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potential for emotional and ﬁnancial harm.
Prevalence Estimates
The goal of screening is to identify pathology that
may predispose to SCD. Further risk stratiﬁcation
of those with a pathological ﬁnding to determine
those at greater or lesser risk of SCD is extremely
challenging because most of our knowledge of
prognosis is derived from symptomatic patients.
Estimates for the community prevalence of con-
ditions predisposing to SCD are provided in
Figure 1. The most common inherited or congenital
pathologies associated with SCD in athletes are
hypertrophic cardiomyopathy (HCM; prevalence
w0.05 to 0.2%) (14–16), anomalous coronary ar-
teries (w0.2%) (17), arrhythmogenic right ventric-
ular cardiomyopathy (ARVC; w0.1%) (18), and
ion-channel disorders (w0.007 to 0.2%) (16,19).
It is noteworthy that these prevalence estimates have
been derived from unselected populations and may
be greater than among athletes in whom a “healthy
cohort” effect tends to select out individuals with
underlying cardiovascular disease. For acquiredheart disease, approximately 0.5% of an asymp-
tomatic population with a median age of 51 years
was identiﬁed as having signiﬁcant coronary artery
disease (20) but this may overstate the risk for our
36-year-old marathon runner with well controlled
coronary risk factors. Thus, we may conservatively
estimate that there is a 1 in 200 (0.5%) risk of any
underlying cardiac condition that may represent a
substrate for SCD in our marathon runner. The
predictive value of any imaging modality is likely to
be poor given this very low disease prevalence. For
example, if the imaging modality were 95% sensitive
and speciﬁc, the predictive value of the test would
only be 9%. In other words, 91% of “abnormalities”
identiﬁed on screening could be expected to repre-
sent a false positive (i.e., they would not represent a
risk for SCD).
These calculations are dependent on speculative
estimates of the sensitivity and speciﬁcity of cardiac
imaging tests for the identiﬁcation of causes of SCD
in asymptomatic populations. There are limited
studies that have assessed the accuracy of imaging
modalities in diagnosing cardiomyopathies and none
of these have been performed in cohorts of asymp-
tomatic athletic adults. This largely reﬂects the fact
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997that clinical diagnoses are seldom based on imaging
alone. ARVC, for example, cannot be diagnosed
solely on the basis of imaging yet can be diagnosed
despite normal appearance on cardiac imaging (21).
The remainder of the review will aim to highlight
the promise and limitations of established and novel
imaging modalities for this purpose.
Most screening algorithms propose imaging as a
“second-line” strategy reserved for those with
abnormal ECGs at rest. Indeed, cardiac imaging is
invaluable for evaluating any athlete with symptoms,
a positive family history, or abnormalities on
screening examination or ECG. However, some
international sporting bodies, such as the Interna-
tional Federation of Association Football (FIFA),
the International Cycling Union (UCI), and the
U.S. National Basketball Association (NBA)
mandate echocardiography as part of primary
screening tests in asymptomatic athletes. The
rationale for combining ECG and imaging to screen
athletes is that pathologies such as channelopathies
and accessory pathways will be identiﬁed with ECG
while coronary anomalies, aortopathies and some
cardiomyopathies may be identiﬁed with imaging
despite a normal ECG. In addition, it may be
argued that in the middle-aged athlete screening
should also address the increasingly appreciable risk
of coronary heart disease. Thus, in the 36-year-old
marathon runner exempliﬁed in this review,
comprehensive screening would need to include an
ECG, imaging of cardiac structure and function,
and some assessment of coronary risk. The
following discussions address whether current im-
aging techniques have the accuracy to effectively
predict athletes at greatest risk of SCD while
minimizing the psychological, physical, and ﬁnan-
cial cost associated with false ﬁndings.
Echocardiography
Echocardiography is a logical candidate as a
screening modality. It is relatively inexpensive and
accessible, and is free of any direct adverse effects.
However, adverse ﬁnancial and psychological side
effects caused through misdiagnosis should not be
overlooked. Thus, it is important to appraise the
accuracy of echocardiography in successfully diag-
nosing pathology among an athletic cohort in whom
profound cardiac remodeling is common.
The greatest body of evidence pertains to the
diagnosis of HCM, which, in most series, is the
predominant cause of SCD in young athletes. Among
others, Maron and Pelliccia (22,23) have provided
extensive data to enable better discriminationbetween “physiological” and “pathological” hyper-
trophy, creating an algorithm in which ventricular
dilation, a maximal oxygen uptake (VO2max)
>110% of predicted and a reduction in hypertrophy
with detraining all suggest physiological “athlete’s
heart” while asymmetry of hypertrophy, left atrial
enlargement, and abnormal diastolic function sug-
gest hypertrophic cardiomyopathy. However, most
of the experience used to formulate these criteria is
derived from comparing athletes and patients with
HCM whereas athletes with HCM frequently do
not follow the rules, and this is especially true of
endurance athletes. Sharma et al. (24) performed 1
of few studies which compared 8 highly trained
athletes to 8 athletes with phenotypically mild, ge-
notype positive HCM and found a considerable
difference in VO2max (66 vs. 33 ml/min/kg, p <
0.001). However, it is difﬁcult to quantify how
much of this difference was due to the altered car-
diac function and how much was due to differences
in athletic conditioning and training volume.
Perhaps surprisingly, it seems that some athletes
with HCM can achieve high levels of cardiovascular
conditioning and can be very competitive in endur-
ance sports (25,26). For example, despite signiﬁcant
pathology, all 3 athletes in Figure 2 competed at an
elite or sub-elite level in triathlon and athlete 3 was
documented as having a VO2max of nearly twice that
predicted for his age.
Of promise is the accumulating evidence base for
tissue Doppler and strain measures in the evaluation
of athletes in whom HCM may be suspected.
D’Andrea et al. (27) have provided a guide for
normal ranges in a moderate sized athletic cohort and
others have extended this experience by comparing
athletes to patients with HCM (28). However, the
study cohort of relatively severe HCM phenotypes
was easily distinguished using the simplest echocar-
diographic measures (e.g., septal thickness 23 vs.
11 mm, p < 0.0001) such that the incremental value
of strain imaging was difﬁcult to assess.
An increasing number of athletes may be diag-
nosed with HCM as a result of genotyping or with
more sensitive diagnostic tools such as delayed
gadolinium enhancement (DGE) identiﬁed with
magnetic resonance imaging. These milder pheno-
types may be compatible with high-level exercise
performance and seem to be associated with few of
the classical diagnostic hallmarks of HCM (25,26).
A recent study by Maron et al. (29) reported that
10% of 114 young patients with asymptomatic
HCM, largely diagnosed by means of DGE and/or
familial studies, had a mild phenotype including a
normal ECG. Thus, while we may easily identify
Figure 2. Increased Sensitivity of Cardiac Magnetic Resonance in Identifying
Pathology
Images from 3 male middle-aged elite triathletes are presented. Athlete 1 presented with
sustained ventricular tachycardia. He had changes consistent with athlete’s heart on
echocardiography (1A) including reduced basal right ventricular (RV) strain (indicated by *
in 1B), which is a common ﬁnding in endurance athletes. However, on cardiac magnetic
resonance imaging there was akinesis of the basal lateral RV free wall corresponding to
areas of delayed enhancement (indicated by z in 1C and 1D) consistent with localized
scarring suggestive of arrhythmogenic right ventricular cardiomyopathy, Athlete 2 pre-
sented with palpitations. He had marked cardiac enlargement on echocardiography (2A
and 2B) but normal systolic function on echocardiography at rest and exercise. Cardiac
magnetic resonance revealed large areas of delayed enhancement of the subepicardium
and mid-myocardium (arrowheads, 2C and 2D) suggestive of a dilated cardiomyopathy.
Athlete 3 survived a ventricular ﬁbrillation arrest during a triathlon race. His left ventricular
wall thickness on echocardiography was at the upper limits of normal (3A) and his diastolic
myocardial velocities were normal (3B). Cardiac magnetic resonance imaging revealed mid-
cavity obstruction during systole (3C) and apical gadolinium enhancement (z, 3D) sug-
gestive of hypertrophic cardiomyopathy.
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998severe HCM by ECG and echocardiography, these
phenotypic extremes are probably very rare among
highly trained athletes.Racial variance in cardiac morphology further
complicates echocardiographic assessment. M-
mode measures of septal wall thickness are the usual
means by which HCM is suspected during an
echocardiographic assessment and descriptions of
the normal distribution of hypertrophy in male
Caucasian athletes suggest that a dimension greater
than 12 mm is rare and should be considered
abnormal pending further investigations (30).
However, 18% of male athletes of African/Afro-
Caribbean have been found to have a septal thick-
ness exceeding 12 mm and similar ethnic differences
have also been reported for female athletes (31). It is
likely that the speciﬁcity of echocardiography would
be substantially reduced when screening athletic
populations of age, gender and ethnic diversity in
which our understanding of normal ranges is limited
(32). As a result, we can be caught in the difﬁcult
situation of excluding athletes on a suspicion that
they may have a disease that may cause SCD. This
could be considered prudent by some and unac-
ceptable by others.
The identiﬁcation of other cardiomyopathies by
echocardiography is similarly problematic. There is
mounting evidence that intense endurance exercise
results in morphological, functional and electrical
remodeling of the right ventricle (RV), which may
be equivalent, if not greater, than that of the left
ventricle (LV) (33–36). Thus, distinguishing
ARVC from the dilated athlete’s heart can be
extremely challenging. Our experience in screening
elite endurance athletes is that the wide variance in
structure and function of the RV creates signiﬁcant
diagnostic uncertainty. Echocardiograms from 4
professional cyclists from the same team are pre-
sented in Online Video 1 illustrating the frequency
in which RV assessment provides clinical chal-
lenges. Important changes to the Task Force criteria
for ARVC diagnosis have qualiﬁed RV enlargement
such that regional abnormalities in structure or
function are now required, thereby reducing the
overlap with athlete’s heart (21). However, identi-
ﬁcation of regional RV abnormalities is imperfect.
Teske et al. (37) performed Doppler and 2D
deformation analysis (strain and strain rate) on pa-
tients with ARVC and found poor agreement be-
tween RV wall motion scoring and identiﬁcation of
regional abnormalities by strain. Even in healthy
patients, the speciﬁcity of regional wall motion
analysis of the RV was insufﬁcient to provide
diagnostic conﬁdence.
Myocarditis and dilated cardiomyopathy have
been implicated in a minority of SCD cases (5,8,12).
Once again, in an asymptomatic population with
Figure 2. Continued
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999extremely high levels of ﬁtness, the accurate identi-
ﬁcation of segmental or global ventricular dilation
and hypokinesis is extremely challenging. Abergel
et al. (38) performed echocardiographic assessments
on 424 cyclists competing in the Tour de France and
found that 51.4% exhibited signiﬁcant LV dilation
and 11.6% had a LV ejection fraction <53%, which
could be compatible with a diagnosis of dilated
cardiomyopathy. Furthermore, Gati et al. (39)
recently reported that 8.1% athletes fulﬁlled con-
ventional criteria for left ventricular noncompaction
syndrome and yet only a very small minority of these
had any other features suspicious of an underlying
cardiomyopathy . Exercise echocardiography may
prove a useful discriminator in these settings. Plehn
et al. (40) reported that exercise caused a reduction
in end-systolic volumes among healthy controls but
not in patients with HCM or a dilated cardiomy-
opathy (40). Exercise echocardiography enables
assessment of cardiac structure, function, and con-
tractile reserve, which can be combined with real-
time ECG data, thus arguably providing greatest
promise as a single test for the exclusion of signiﬁ-
cant pathology in athletes in whom there is clinical
suspicion. However, its predictive value in unselected
athletic populations is insufﬁcient to accurately pre-
dict the rare athlete at risk of SCD.
Ischemic cardiac disease, either due to anomalous
coronaries or acquired atherosclerotic disease should
be excluded as a potential cause of SCD. It has been
demonstrated that the coronary ostia can be visu-
alized in 90% to 92% of athletes using echocardi-
ography and that the identiﬁcation of anomalous
ostia is highly speciﬁc (41,42). However, the sen-
sitivity of echocardiography in detecting congenital
coronary anomalies (the ability to identify all cases)
has yet to be assessed, and it requires an experienced
sonographer and good image quality to conﬁdently
identify the ostia and proximal course of the coro-
nary circulation. Outside the realm of screening, in
those athletes with exertional symptoms in which
coronary anomalies may be suspected, it is advisable
to consider computed tomography coronary angi-
ography (CTCA) and/or cardiac magnetic reso-
nance (CMR), which are highly accurate methods
for identifying the precise anatomy of coronary
anomalies (43).
Echocardiography may accurately identify prox-
imal aortic dilatation and/or bicuspid aortic valve
disease that may prevent some cases of SCD due to
aortic dissection. Data from large cohorts of ath-
letes have provided a clear deﬁnition of expected
normal ranges of aortic size (44,45). While aortic
dimensions are slightly increased in athletic cohortsthe difference is of minimal clinical signiﬁcance
and aortic root dimension of >40 mm in males or
>34 mm in females should be considered
abnormal. These represent useful diagnostic cutoffs
for screening and may identify small numbers of
athletes with severely dilated aortas at signiﬁcant
risk of dissection. On the other hand, some athletes
will be identiﬁed with milder dilation in whom
there is little evidence to direct advice on sports
participation. Posing similar management issues,
bicuspid aortic valve (BAV) pathology can be
identiﬁed in as many as 2.5% of athletes under-
going echocardiographic screening (46). Identiﬁ-
cation of athletes with BAV may be helpful in
identifying athletes in whom regular follow-up may
prevent asymptomatic LV deterioration, particu-
larly in the context of severe aortic regurgitation,
although there is again limited evidence on the
degree to which exercise modiﬁes the natural pro-
gression of the disease. One may also argue that the
majority of athletes with valvular complications
secondary to BAV would be identiﬁed on physical
examination and that progressive LV remodeling
may result in ECG changes. Thus, while echo-
cardiography will reliably identify aortopathies and
BAV, the number of lives saved as a result of
screening is likely to be very small. Although
focused echocardiographic studies using portable or
hand-held devices may minimize costs, echocardi-
ography still requires considerable resource infra-
structure and operator skill. This is likely to be
prohibitive in most settings, with the possible
exception of sports such as basketball in which
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common.
Zeltser et al. (47) provide some insight into
the potential limitations of a pre-participation
screening program inclusive of an echocardio-
graphic examination. They screened 2,051 high-
school athletes with a “limited” echocardiographic
examination comprising 2-dimensional measures of
cardiac structure, volumes, and ejection fraction.
Fourteen athletes (0.7%) were considered to have
changes on echocardiogram suspicious of disease
(10 HCM, 2 noncompaction, 1 dilated cardiomy-
opathy, and 1 subaortic stenosis), all but 3 of which
had ECG changes that would have prompted
further evaluation in any case. Of the 14 athletes
with suspicious changes on screening echocardiog-
raphy, 6 refused follow-up, 5 were considered
normal after a more comprehensive echocardiogram,
and 3 athletes were diagnosed with a cardiomyop-
athy (2 HCM, 1 noncompaction). However, none
of these 3 diagnoses were subsequently conﬁrmed by
a blinded expert at an independent institution.
Thus, this initial real-world experience would sug-
gest that routine echocardiography has the potential
to inappropriately exclude athletes while having
limited or no efﬁcacy in detecting pathological
disease with potential for SCD.
Acquired atherosclerotic coronary disease may be
identiﬁed using exercise echocardiography with
moderate sensitivity and speciﬁcity (approximately
76% and 88%, respectively), comparing favorably
with other stress-testing methods (48). However,
few asymptomatic middle-aged athletes will have
risk factors constituting intermediate pre-test like-
lihood by standardized criteria such as the
Diamond-Forrester method or Duke Clinical Score
(49,50), and thus exercise testing should not be
recommended (51). Furthermore, while a positive
stress test may be a good predictor of subsequent
angina, it may not be a good predictor of subsequent
myocardial infarction or SCD because the former
requires an existing signiﬁcant stenosis whereas the
later generally occur in a nonobstructing lesion that
experiences plaque disruption.
In the 36-year-old experienced marathon runner
seeking medical clearance cited in this review, an
echocardiogram was performed. As demonstrated in
OnlineVideo 2, therewere typical features of athlete’s
heart with moderate enlargement of all 4 cardiac
chambers, particularly of the right atrium and right
ventricle (Fig. 3). There was mild hypertrophy of the
septum (11mm) and of theRV freewall (6mm). Low
normal systolic function was conﬁrmed with 3D
echocardiography. Strain and strain rate of the RVfree wall demonstrated considerable heterogeneity
with reduced values for the basal and mid segments.
While each of these values is within the ranges
commonly seen in highly trained athletes, they differ
considerably from that which we would consider
normal for a nonathlete. The borderline systolic
function and low regional deformation make it
difﬁcult to conclusively exclude pathology.
CMR
CMR has considerable promise in the evaluation of
the heart of an athlete. As compared with echo-
cardiography, CMR enables better assessment of
the morphology and function of all cardiac cham-
bers while also enabling tissue characterization by
means of T2-weighted imaging of acute edema and
DGE assessment of focal and diffuse ﬁbrosis (52).
Recent developments suggest CMR may also
become a gold standard means of assessing cardiac
function during exercise (53).
In the recent era in which familial cardiomyop-
athies are being diagnosed using cascade screening
of effected family members, it is increasingly
recognized that CMR represents a more sensitive
diagnostic tool. As compared with ECG and
echocardiography, CMR including DGE assess-
ment can identify athletes when the ECG and
echocardiography are normal (29) (Fig. 2). Thus,
CMR should be considered the most comprehen-
sive imaging modality for the exclusion of pathol-
ogy, making it an extremely valuable imaging
modality for assessing athletes with concerning
symptoms. However, the relative expense and
limited availability of CMR make it less suitable for
broad-based screening and the speciﬁcity of CMR
testing in athletes with little pre-test probability for
disease is not sufﬁciently high to preclude a signif-
icant burden of false positive results.
The accurate differentiation of normal athlete’s
heart from pathology is largely dependent upon our
understanding of what constitutes normal. While we
now have echocardiographic values from many
thousands of athletes of differing demographics and
sporting practices, normal CMR values are far less
numerous, derived from few centers and from a less
diverse sporting population. The largest experience
describing the normal range of cardiac morphology
and function is provided by the Utrecht group
of Prakken et al. (54) who compared biventricular
volumes, masses, and dimensions in 222 endurance
athletes (79 elite and 143 recreational, 42% female)
with 114 age and sex-matched nonathletes. They
have also described morphological differences
Figure 3. The “Gray Zone” in Established and Novel Echocardiographic Measures of a 36-Year-Old Well-Trained Marathon Runner
Echocardiographic measures are demonstrated for the healthy marathon runner exempliﬁed in this review. As is common in athletes,
all 4 cardiac chambers are enlarged. M-mode measures demonstrate moderate left ventricular dilation and mild hypertrophy (A). The
2-dimensional atrial areas are mild to moderately increased (B), while 3-dimensional volumes are moderate (LV) to severely (RV) enlarged
when compared with reference ranges derived from nonathletic populations (E). Color-coded Doppler derived strain (C) and strain rate (D)
demonstrate mildly reduced basal strain and strain rate values (as indicated by the orange arrows). Many of these measurement values
overlap with those of cardiomyopathies and there are currently very few diagnostic cutoff values that enable us to risk-stratify asymp-
tomatic athletes with accuracy. Online Video 1 demonstrates unusual RV dilation and function in 4 professional cyclists, thus, further
illustrating the difﬁculties in separating health from disease in asymptomatic athletes. Cardiac magnetic resonance imaging of our middle-
aged marathon runner does not always resolve uncertainty, as illustrated in Online Video 2. EDV ¼ end-diastolic volume; EF ¼ ejection
fraction; LV ¼ left ventricle; RV ¼ right ventricle.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 9 , 2 0 1 3 La Gerche et al.
S E P T E M B E R 2 0 1 3 : 9 9 3 – 1 0 0 7 Imaging Asymptomatic Athletes
1001in cardiac adaptation according to training and
sport type in a manner similar to the experience
with echocardiography (55,56). Interestingly, they
report the only direct comparison between CMR
and echocardiography in the assessment of athletes’
cardiac morphology in which, similar to non-
athletic ﬁndings, measures of cardiac volumes are
consistently larger while wall thickness and mass
were lower when measured by CMR (57). In total,
this constitutes an impressive body of work butthe application of this single-center experience in
clinical decision making may be confounded by
operator-speciﬁc differences in image acquisition
and analysis techniques. For example, considerable
differences between ventricular volumes determined
from axial, as compared with short-axis acquisitions,
have been observed even when analyzed at
1 institution using the same software (58,59). Thus, a
broader and larger experience of healthy athlete
CMR values is required prior to being able to use
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1002these to accurately identify athletes who have cardiac
dimensions that may be considered abnormal.
Recently, there has been considerable interest
generated by a number of studies in which DGE has
been observed within the LV myocardium of
ostensibly healthy athletes (33,60,61). It has been
hypothesized that these small patches of DGE
found in 12% to 50% of extensively trained veteran
athletes may represent ﬁbrosis resulting from
extreme physical training (33,61). However, there
are still very limited data on which to assess causality
and there are a number of studies that have reported
that DGE is not a feature of athlete’s heart, albeit in
younger, less trained cohorts (62–64). The fact that
the DGE has been observed in healthy athletic
cohorts would suggest that it is of limited clinical
signiﬁcance and we have no long-term clinical data
to suggest otherwise. Recently, Trivax et al. (65)
described the case of a middle-aged runner in
whom aborted SCD was attributed to proar-
rhythmic myocardial ﬁbrosis, as evidenced by a
small patch of DGE (Fig. 4). However, if these
changes may be identiﬁed in approximately 12% of
asymptomatic “healthy” athletes then it may be
presumptive to cite this as the probable cause of
cardiac arrest. Moreover, if CMR with DGE is used
to assess asymptomatic athletes then what advice do
we offer the athlete in whom DGE is identiﬁed?
We contend that there is a clear need to assess the
long-term consequences of these ﬁndings but, in the
meantime, there is no evidence on which to advise
athletes of an increased risk of events. Perhaps more
than anything, it highlights the need to have a good
reason for doing a test which is expensive, time
consuming, may include the use of contrast agents
(with a small but deﬁnite risk) and, in some cases,
may increase the level of uncertainty for the athlete
and clinician.
Coronary Artery Calcium Scoring and CTCA
For the 36-year-old marathon runner featured in
this review, acquired coronary vascular disease rep-
resents 1 of the greater risks for SCD. Kim et al.
(66) reported that among marathons completed in
the United States, 2 in every 100,000 male athletes
(mean age 52 years) suffered SCD, an incidence
that seems to have increased in recent years. Among
the 8 survivors of cardiac arrest in this study,
causation was attributed to nonobstructive athero-
sclerotic disease in 5 athletes, none of whom had
angiographic evidence of ruptured plaque. This
raises the question as to whether otherwise stable
coronary artery disease could constitute a risk forSCD among the milieu of hemodynamic, cate-
cholaminergic, and other stresses during a mara-
thon. In this context, if screening were to be
performed in our 36-year-old athlete, it may be
prudent to include evaluation of his coronary arteries
with CACS and/or CTCA. Both have been pro-
moted as “promising tools” for screening asymp-
tomatic veteran athletes (60,67) on the basis that
they have proven value over clinical risk factors in
the prediction of myocardial infarction and SCD,
particularly among those of intermediate risk
(16,68). However, there are a number of arguments
against screening asymptomatic athletes with coro-
nary artery calcium scoring (CACS) and CTCA.
Apart from the ﬁnancial cost of screening a low-risk
cohort and the potential to cause harm due to
contrast reactions and radiation exposure (accepting
that this has been substantially reduced and now
constitutes a relatively small dose), 1 prime concern
is whether a signiﬁcant ﬁnding on CACS or CTCA
changes the management of the athlete. It is
frequently argued that informing an asymptomatic
individual of the presence, or likely presence, of
coronary artery disease will increase physician and
patient motivation to aggressively adhere to phar-
macological and lifestyle prevention interventions
(69). There have been 2 randomized controlled
trials that investigated this hypothesis. Rozanski
et al. (70) randomized 1,424 subjects to risk factor
management including CACS and 713 subjects to
management without CACS and determined that
scanned subjects had a slightly greater reduction in
systolic blood pressure (–7 mm Hg vs. –5 mm Hg,
p ¼ 0.02) and low-density lipoprotein cholesterol
(–17% vs. –11%, p ¼ 0.04), but there was no dif-
ference in medication adherence, smoking cessation
or exercise and the CACS strategy tended to be
more expensive ($US 4,053 vs. $3,649, p ¼ 0.09).
O’Malley et al. (71) randomized 450 asymptomatic
middle-aged army personnel who underwent CACS
to either have their results known or withheld.
Knowledge of CACS did not inﬂuence treatment
adherence, intervention initiation or the extent to
which risk factor management improved. Despite
this relatively modest evidence for incremental
beneﬁt of CACS beyond traditional risk factor
guided management, recent American College of
Cardiology/American Heart Association guidelines
support its use in asymptomatic individuals with
intermediate cardiovascular risk (10% to 90% Fra-
mingham risk) but regard CACS as inappropriate
for those of low risk (72). It would seem, therefore,
that few athletes would beneﬁt from CACS. If
considering the study of Mohlenkamp et al. (60),
Figure 4. Delayed Gadolinium Enhancement in 2 Competitive Runners With Very Different Clinical Outcomes
Cardiac magnetic resonance images of consecutive short-axis slices following gadolinium contrast are demonstrated. The 3 images are taken
from a case report of an athlete who survived sudden cardiac death. The authors speculated that the patch of delayed gadolinium
enhancement in the anteroseptal wall of the left ventricle (LV) (yellow arrows) may represent pro-arrhythmic myocardial ﬁbrosis resulting
from extreme exercise training (65). On the other hand, similar ﬁndings have been found in 12 to 50% of well-trained endurance athletes
(33,60,61). In the case of the apparently healthy 36-year-old marathon runner undergoing screening in this review, there is a similar small
patch of delayed gadolinium enhancement in the posteroseptum of the LV. Given the uncertainty of the signiﬁcance of these ﬁndings,
identiﬁcation of small patches of delayed gadolinium enhancement on screening may be of limited clinical value in older endurance athletes.
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older had a Framingham risk prediction of >10%.
According to American College of Cardiology/
American Heart Association guidelines, there is no
role for CTCA screening of asymptomatic individuals
of low or moderate cardiovascular risk according to
American Heart Association guidelines (72).
Exercise Testing
A number of studies have demonstrated that an
abnormal exercise ECG test is associated with car-
diovascular events, total mortality, and SCD in
asymptomatic adults (1,73,74). However, it is also
notable that the predominant risk factor is low ﬁtness.
An exercise capacity of greater than 8 to 10 METs
(approximating a VO2max of 28 to 35 ml/min/kg or
the ability to run slowly) is associated with fewer
cardiovascular events and greater longevity in men
and women, the predictive value of which exceeds any
information provided from ECG changes during the
test (73,74). Even among adults with a moderate to
high risk of coronary vessel disease, signiﬁcant
myocardial ischemia is uncommon among those with
a maximal exercise tolerance >10 METs (75). Thus,
the simplest and most cost-effective risk stratiﬁcation
would be to simply determine whether an adult isable to swim or jog at low to moderate intensity and
directing further assessment at those who cannot.
Athletes, virtually by deﬁnition, pass this test and
have an excellent prognosis. Further testing will have
limited impact on further reﬁning this risk and is not
recommended except in those who are planning on
entering vigorous competitive situations and who
have moderate-to-high cardiovascular risk proﬁles
(76,77). There is no evidence to guide recommen-
dations in athletes already engaged in vigorous
sporting activities, such as the seasoned marathon
runner exempliﬁed in this review. If we conclude that
the most predictive feature on exercise testing is
ﬁtness, then the answer is apparent before the athlete
steps on the treadmill and any abnormality is, sta-
tistically, most likely to be benign.
Soﬁ et al. (78) provide the only large-scale evalu-
ation of exercise stress testing in pre-participation
screening for competitive sports. Drawing from the
Italian experience in which exercise ECG testing has
been a mandated part of pre-participation screening
since 1982, the study reported the results of over
30,000 referrals for screening. The unselected pop-
ulation included a very broad age range (5 to 92 years,
mean ¼ 31 years) and a combination of well-trained
athletes and nonathletes seeking to commence sport.
Abnormalities were detected in 4.9% leading to
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1004disqualiﬁcation from competitive sport in 0.6% of the
total population. The efﬁcacy of these exclusions in
preventing SCD remains unknown.
Cardiac Imaging as a Second-Line Screening Tool
While there is no evidence to support cardiac im-
aging as a primary modality in screening asymp-
tomatic athletes, it becomes of prime relevance in the
evaluation of athletes in whom an abnormality is
identiﬁed on ECG. Recently reﬁned recommenda-
tions aim to increase the speciﬁcity of the screening
ECG in athletes to>97% (79). If achieved, it may be
expected that the prevalence of underlying cardiac
disease will be far greater among those 3% of athletes
with signiﬁcant abnormalities on ECG. Thus, ac-
cording to Bayes’ theorem, the predictive value of
cardiac imaging is much improved. Further testing
should be applied on a case-by-case basis and should
focus on appraising the differential diagnoses arising
from the clinical examination, history and ECG.
The ﬂowchart provided in Figure 5 illustrates the
manner in which a hierarchy of cardiac imaging
modalities may enable differentiation of healthy
athletes from those with conditions that requireStructural Heart Disease
Confirmed (n = 200)
Structural Heart Disease
Confirmed (n = 80)
Congenital or Acquired
Coronary Disease
Confirmed (n = 10)
Channe
lopathy 
Identifie
d (n = 10)
Access
ory Path
way (n = 1
00)
Inconclusive CMR n
Age  < 35
? Anomalous Corona
Definitive or
Probable Pathology
- Further management
± disqualification
(n = 300)
Cardiac Magn
Resonance Ima
Repeat Imaging
After 12 Months or
a Period of Detraining
CT Coronar
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Ech
Figure 5. Screening 100,000 Asymptomatic Athletes Using a Hierar
This ﬂowchart provides an algorithm whereby cardiac imaging may be
the “at-risk” population by means of electrocardiogram (ECG) screening
serious pathology is identiﬁed (100% sensitivity) and no healthy athletes
the cascade of tests. CMR ¼ cardiac magnetic resonance; CT ¼ compufurther management to minimize the risk of SCD.
This chart is unable to reﬂect the considerable
ﬂexibility required of clinical decision making. For
example, in the athlete with deep T-wave inversion
in anteroseptal leads (raising the suspicion of ARVC)
or inferolateral leads (HCM), the clinician may be
ill-advised to reassure the athlete even if the echo-
cardiographic study were to appear normal. In this
scenario, a subtle cardiomyopathy may be evident
on CMR or may evolve with time, thus necessitating
careful surveillance.
Conclusions
Athletes represent a group in whom the risks of
cardiovascular events and SCD are extremely low.
The causes of SCD are relatively diverse and are not
accurately identiﬁed by any 1 imaging test, especially
in the middle-aged athlete who represents a sub-
stantial proportion of competitive sports participa-
tion. At present, we have an incomplete
understanding of what constitutes the normal range
of cardiac morphology and function among athletes
of all ages and ethnicities. This is especially true for
novel techniques and imaging modalities other thanNormal (n = 220)
Normal and/or
Annual Follow-up (n = 90)
Normal
(n = 2,290)
Normal
(n = 97,000)
?? Role Remains Controversial
Inconclusive ECG
n = 2,890
Inconclusive Echo
n = 400
 = 100
ry Ostia
Age > 35
? Acquired Coronary Disease
100,000 Asymptomatic Athletes
(including approximately 400 athletes
with underlying pathology)
12-lead
Electrocardiogram
etic
ging
Stress Test and/or
Coronary Artery
Calcium Scoring
y
ocardiogram
Fit to Play
(n = 99,600)
chy of Cardiac Imaging Modalities
employed as secondary screening modality following reﬁnement of
. This ﬂowchart represents an ideal scenario in which all potentially
are incorrectly diagnosed with pathology (100% speciﬁcity) following
ted tomography.
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1005the most basic echocardiographic measures. As
exempliﬁed by the examples in this review, atypical
ﬁndings such as marked cardiac dilation, reduced
deformation or small patches of delayed gadolinium
enhancement may introduce uncertainty in the
asymptomatic athlete in whom the risk of SCD is
extremely small. Therefore, we do not believe that
cardiac imaging can be recommended as a ﬁrst-line
screening tool. Rather, patient speciﬁc in-
vestigations should be focused on evaluating those
athletes in whom clinical suspicion is raised by
symptoms, family history, clinical exam and/or ab-
normalities on ECG. While it is imperative that we
continue our efforts to safeguard athletes, we mustalso recognize the current limitations of our tools in
predicting SCD in low-risk populations.Acknowledgements
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